

Long-term pain relief and functional recovery after one-step cartilage repair with Hyalofast plus BMAC - successful outcomes maintained up to 14 years post-surgery

Introduction

Articular cartilage injuries can severely impact joint function and overall quality of life. Left untreated, these lesions often progress to advanced degeneration requiring total joint replacement. Several techniques have been developed to preserve joint function, including bone marrow stimulation, osteochondral grafting, cell-free scaffolds, and cell-based regenerative techniques.^{1,2,3} Although traditional regenerative options like ACI/MACI, demonstrated the ability to restore durable articular cartilage tissue, they involve multiple surgeries, high costs, and regulatory barriers due to cell culture requirements.

Hyalofast is a scaffold made of hyaluronic acid fibers which, combined with Bone Marrow Aspirate Concentrate (BMAC), offers a single-step regenerative alternative. Clinical studies have demonstrated promising

outcomes for both knee and ankle cartilage repair.^{4,5} Imaging and histological data reveal the formation of hyaline-like cartilage tissue, suggesting long-lasting improvement in joint function and symptom relief.^{6,7,8,9}

While short and mid-term evidence is encouraging, long-term outcomes are essential, especially for active patients undergoing surgery at a young age. Here we present main clinical findings showing sustained pain reduction and functional stability for up to 14 years post-treatment using the Hyalofast plus BMAC approach. The investigation was conducted by the OASI (Orthopedic Arthroscopic Surgery International) Bioresearch Foundation group (Milan, Italy) and published in two clinical peer-reviewed articles.^{10,11}

Key Highlights



Significant and Durable pain relief and improved joint function maintained over the long term
(mean follow-up of 14 years)



Kaplan-Meier survival analysis showed durable clinical results:

- 92% survival rate at 5 years
- 88% survival rate at 10 years
- 88% survival rate at 14 years

Overview

Hyalofast plus BMAC represents a reliable single-step cartilage repair technique for treating full-thickness knee cartilage lesions as described in previous studies, on the same patient population with effectiveness up to 8 years.¹⁰

Objective: assess the effectiveness of Hyalofast plus BMAC to provide a stable improvement over time.

Study Design: prospective case series with 26 patients treated between April 2007 and January 2012

Inclusion Criteria:

- Grade 4 knee cartilage lesion (ICRS criteria)
- Defect size $\geq 1 \text{ cm}^2$
- Age: 30–60 years old
- BMI (Body Mass Index): 20–30
- Active lifestyle (≥ 2 sport sessions/week)

Follow-Up Duration: 12–16 years (mean 14 years)

Clinical Evaluation Tools:

- KOOS (Knee injury and Osteoarthritis Outcome Score)¹²
- VAS (Visual Analogue Scale)

Study Results



Patients

26 (mean age 48.3)
Median lesion size 6.6cm²



Follow-up

Mean 14 years
Lost to follow-up:
4 pts



Pain Relief

VAS Pain decreased from
5.0 pre-op to 0.3 at 8
years, remaining almost
stable at 14 years (0.6)
(P<.001) Table 1, Fig 1



KOOS

All subscales improved
almost stable, when
compared 14-year values to
8-year data
(P<.001) Table 1, Fig 2



Durability

Survival rate:
5 years: 92%
10-14 years: 88%
Fig 3

TABLE 1

Comparison of clinical outcome scores at each follow up time point.^{10,11}

Score Type	Mean Score Values				P Value
	Pre-op (N=26)	2 years (N=23)	8 years (N=23)	14 years (N=22)	
KOOS					
Sport	30	78	85	85	<0.001
Pain	57	94	94	92	<0.001
Symptoms	60	91	89	86	<0.001
ADL	65	95	99	96	<0.001
QOL	25	83	85	88	<0.001
VAS	5	1	0.3	0.6	<0.001

ADL activities of daily living; KOOS, Knee injury and Osteoarthritis Outcome Score; QOL, quality of life; VAS, visual analog scale.

FIGURE 1


VAS from baseline to final mean follow-up (14 years)



VAS, visual analog scale

FIGURE 2

KOOS subscales from baseline to mean final follow up (14 years)



ADL activities of daily living; KOOS, Knee injury and Osteoarthritis Outcome Score; QOL, quality of life

FIGURE 3

Kaplan-Meier survival plot after treatment of full thickness knee chondral injury with Hyalofast scaffold and BMAC



Conclusion

One-step cartilage repair using Hyalofast combined with BMAC delivers proven, long-term successful clinical results for full-thickness knee chondral defects. Clinical outcomes demonstrated sustained pain relief and preserve joint function over an average follow-up of 14 years, underscoring the durability and stability of this regenerative treatment.

- De Caro F, Bisicchia S, Amendola A, Ding L. Large fresh osteochondral allografts of the knee: a systematic clinical and basic science review of the literature. *Arthroscopy*. 2015;31(4):757-765.
- Ogura T, Bryant T, Merkely G, Minas T. Autologous chondrocyte implantation for bipolar chondral lesions in the patellofemoral compartment: clinical outcomes at a mean 9 years' follow-up. *Am J Sports Med*. 2019;47(4):837-846.
- Perdisa F, Filardo G, Sessa A, et al. One-step treatment for patellar cartilage defects with a cell-free osteochondral scaffold: a prospective clinical and MRI evaluation. *Am J Sports Med*. 2017;45(7):1581-1588.
- Buda R, Vannini F, Cavallo M, Grigolo B, Cenacchi A, Giannini S. Osteochondral lesions of the knee: a new one-step repair technique with bone-marrow-derived cells. *J Bone Joint Surg Am* 2010; 92 (Suppl 2):2-11
- Giannini S, Buda R, Vannini F, Cavallo M, Grigolo B. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. *Clin Orthop Relat Res* 2009; 467:3307-3320
- Giannini S, Buda R, Battaglia M, Cavallo M, Ruffilli A, Ramponi L et al (2013) One-step repair in talar osteochondral lesions: 4-year clinical results and T2-mapping capability in outcome prediction. *Am J Sports Med* 41:511-518
- Vannini F, Battaglia M, Buda R, Cavallo M, Giannini S. "Onestep" treatment of juvenile osteochondritis dissecans in the knee: clinical results and T2mapping characterisation. *Orthop Clin North Am*. 2012;43(2):237-44.
- Gobbi A, Chaurasia S, Karnatzikos G, Nakamura N. Matrix-Induced Autologous Chondrocyte Implantation versus Multipotent Stem Cells for the Treatment of Large Patellofemoral Chondral Lesions: A Nonrandomized Prospective Trial. *Cartilage*. 2015 Apr;6(2):82-97.
- Gobbi A, Whyte GP. One-Stage Cartilage Repair Using a Hyaluronic Acid-Based Scaffold With Activated Bone Marrow-Derived Mesenchymal Stem Cells Compared With Microfracture: Five-Year Follow-up. *Am J Sports Med*. 2016 Nov;44(11):2846-2854.
- Gobbi A, Whyte GP. Long-term Clinical Outcomes of One-Stage Cartilage Repair in the Knee With Hyaluronic Acid-Based Scaffold Embedded With Mesenchymal Stem Cells Sourced From Bone Marrow Aspirate Concentrate. *Am J Sports Med*. 2019 Jun;47(7):1621-1628.
- Whyte GP, Bizzoco L, Gobbi A. One-Step Cartilage Repair of Full-Thickness Knee Chondral Lesions Using a Hyaluronic Acid-Based Scaffold Embedded With Bone Marrow Aspirate Concentrate Long-term Outcomes After Mean Follow-up Duration of 14 Years. *Am J Sports Med*. 2024 Dec;52(14):3561-3568.
- KOOS User's Guide 2.0 Updated January 2025

Anika Therapeutics S.r.l.

Corso Stati Uniti 4/U - 35127 Padova, Italy
0039 049-295-8311 | salessupportitaly@anika.com
www.anika.com | Anika. Restore Active Living.™ | Stay Active®

Hyalofast is not approved for use in the United States.

The information contained in this brochure applies exclusively to territories outside of North America.

Anika, Hyaff, Stay Active, and Restore Active Living are trademarks and/or registered trademarks of Anika Therapeutics, Inc. and its affiliates

in certain jurisdictions. Hyalofast is a registered trademark of Fidia Farmaceutici S.p.a. licensed exclusively to Anika Therapeutics S.r.l.

©2026 Anika Therapeutics, Inc. All rights reserved.

AML-900-771 REV 01

